Isolation of new flavonol triglycosides shows potential benefits in Bergera koenigii, indicating diverse compounds.
A new flavonol triglycoside, 4ʹ‐ O ‐ β ‐glucopyranosyl‐isorhamnetin 3‐ O ‐ α ‐ l ‐rhamnopyranosyl‐(1→6)‐ β ‐ d ‐galactopyranoside (or bergeroside, ( 1 ) together with isorhamnetin 3‐ O ‐ α ‐ l ‐rhamnopyranosyl‐(1→6)‐ β ‐ d ‐galactopyranoside ( 2 ), isorhamnetin 3‐ O ‐ α ‐ l ‐rhamnopyranosyl‐(1→2)‐[ α ‐ l ‐rhamnopyranosyl‐(1→6)‐ β ‐ d ‐galactopyranoside] ( 3 ), kaempferol 3‐ O ‐ α ‐ l ‐rhamnopyranosyl‐(1→6)‐ β ‐ d ‐galactopyranoside ( 4 ), kaempferol 3‐ O ‐ α ‐ l ‐rhamnopyranosyl‐(1→2)‐[ α ‐ l ‐rhamnopyranosyl‐(1→6)‐ β ‐ d ‐galactopyranoside] ( 5 ), benzyl β ‐ d ‐glucopyranoside ( 6 ), eugenol rutinoside ( 7 ), 4‐ E ‐propenyl‐phenol‐1‐ O ‐ α ‐ l ‐rhamnopyranosyl‐(1→6)‐ β ‐ d ‐glucopyranoside ( 8 ), and icariside B 1 ( 9 ) were isolated from the leaves of Bergera koenigii . The structure determinations were considered based on the physical data and spectroscopic evidence, including 1D and 2D NMR experiments.
No takes yet. Share an insight, caveat, or question.
Thumtamala et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: